Real World Experience in Effect of Torsemide Vs. Furosemide After Discharge in Patients with HFpEF

Overview

Journal ESC Heart Fail

Date 2024 Sep 6

PMID 39238285

Authors

Xiao Li

Jinping Si

Ying Liu

Danyan Xu

Affiliations

Soon will be listed here.

Abstract

Aims: Few studies have focused on the effect of torsemide versus furosemide after discharge on prognosis in patients with heart failure with preserved ejection fraction (HFpEF). This single-centre retrospective real-world study was conducted to evaluate the effect of torsemide versus furosemide after discharge on all-cause mortality and rehospitalization for heart failure in patients with HFpEF.

Methods: Consecutive patients who were diagnosis with HFpEF after discharge between January 2015 and April 2018 at the First Affiliated Hospital of Dalian Medical University and who had been treated with torsemide or furosemide were included in this study. The primary outcome was all-cause mortality. The second outcome was rehospitalization for heart failure.

Results: A total of 445 patients (mean age 68.56 ± 8.07, female 55%) were divided into the torsemide group (N = 258) or furosemide group (N = 187) based on the treatment course at discharge from the hospital. During a mean follow-up of 87.67 ± 11.15 months, death occurred in 68 of 258 patients (26.36%) in the torsemide group and 60 of 187 patients (30.09%) in the furosemide group [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.57-1.15, P = 0.239]. Rehospitalization for heart failure occurred in 111 of 258 patients (43.02%) in the torsemide groups and 110 of 187 patients (58.82%) in the furosemide group (HR 0.64, 95% CI 0.49-0.85, P = 0.002).

Conclusions: Compared with furosemide, torsemide did not significantly reduce all-cause mortality, but there was association between torsemide and reduced rehospitalization for heart failure in patients with HFpEF.

Citing Articles

Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF.

Li X, Si J, Liu Y, Xu D ESC Heart Fail. 2024; 12(1):71-79.

PMID: 39238285 PMC: 11769599. DOI: 10.1002/ehf2.15071.

References

Bello N, Claggett B, Desai A, McMurray J, Granger C, Yusuf S . Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail. 2014; 7(4):590-5. PMC: 4102617. DOI: 10.1161/CIRCHEARTFAILURE.113.001281. View

Peters A, Mentz R, DeWald T, Greene S . An evaluation of torsemide in patients with heart failure and renal disease. Expert Rev Cardiovasc Ther. 2021; 20(1):5-11. PMC: 8887994. DOI: 10.1080/14779072.2022.2022474. View

Omote K, Verbrugge F, Sorimachi H, Omar M, Popovic D, Obokata M . Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur J Heart Fail. 2022; 25(2):185-196. PMC: 9974926. DOI: 10.1002/ejhf.2747. View

Mazurek M, Huisman M, Lip G . Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. Am J Med. 2016; 130(2):135-145. DOI: 10.1016/j.amjmed.2016.09.012. View

Dunlay S, Roger V, Redfield M . Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 14(10):591-602. DOI: 10.1038/nrcardio.2017.65. View

Seko Y, Kato T, Morimoto T, Yaku H, Inuzuka Y, Tamaki Y . Association between changes in loop diuretic dose and outcomes in acute heart failure. ESC Heart Fail. 2023; 10(3):1757-1770. PMC: 10192247. DOI: 10.1002/ehf2.14338. View

Tsao C, Aday A, Almarzooq Z, Alonso A, Beaton A, Bittencourt M . Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022; 145(8):e153-e639. DOI: 10.1161/CIR.0000000000001052. View

Trippel T, Van Linthout S, Westermann D, Lindhorst R, Sandek A, Ernst S . Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). Eur J Heart Fail. 2017; 20(3):460-470. DOI: 10.1002/ejhf.960. View

Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

10.

. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022; 28(5):e1-e167. DOI: 10.1016/j.cardfail.2022.02.010. View

11.

Greene S, OBrien E, Mentz R, Luo N, Hardy N, Laskey W . Home-Time After Discharge Among Patients Hospitalized With Heart Failure. J Am Coll Cardiol. 2018; 71(23):2643-2652. PMC: 6742493. DOI: 10.1016/j.jacc.2018.03.517. View

12.

Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S . Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023; 329(3):214-223. PMC: 9857435. DOI: 10.1001/jama.2022.23924. View

13.

Khan M, Greene S, Hellkamp A, DeVore A, Shen X, Albert N . Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021; 14(11):e008351. DOI: 10.1161/CIRCHEARTFAILURE.121.008351. View

14.

Li X, Si J, Liu Y, Xu D . Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF. ESC Heart Fail. 2024; 12(1):71-79. PMC: 11769599. DOI: 10.1002/ehf2.15071. View

15.

Baudry G, Coutance G, Dorent R, Bauer F, Blanchart K, Boignard A . Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation. ESC Heart Fail. 2023; 10(5):2843-2852. PMC: 10567662. DOI: 10.1002/ehf2.14467. View

16.

Redfield M, Borlaug B . Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023; 329(10):827-838. DOI: 10.1001/jama.2023.2020. View

17.

Murray M, Deer M, Ferguson J, Dexter P, Bennett S, Perkins S . Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001; 111(7):513-20. DOI: 10.1016/s0002-9343(01)00903-2. View

18.

Carson P, Anand I, Win S, Rector T, Haass M, Lopez-Sendon J . The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC Heart Fail. 2015; 3(6):429-441. DOI: 10.1016/j.jchf.2014.12.017. View

19.

Ellison D, Felker G . Diuretic Treatment in Heart Failure. N Engl J Med. 2017; 377(20):1964-1975. PMC: 5811193. DOI: 10.1056/NEJMra1703100. View

20.

Gerber Y, Weston S, Redfield M, Chamberlain A, Manemann S, Jiang R . A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015; 175(6):996-1004. PMC: 4451405. DOI: 10.1001/jamainternmed.2015.0924. View